To The Moon

Please find and follow my YT channel (nerdbull1669) for Daily SG and US Stock Watchlist.

Do follow me as I share quality stock pick for Daily Watchlist.

As I have previous posted an article on rotation happening for defensive stocks (traditionally it is tech stocks), it seem like we can see some shift to health care sector stocks in particular, pharmaceutical.

Rotation Coming, look at Defensive and Health Care Stocks

I have done a summary of what my A.I. model has predicted and the result and performance of each prediction.

There has been either pharmaceutical, therapeutic, bioscience, health care or health tech stocks in the daily prediction.

This could show that there is a shift from previously stocks which is more into A.I., tech or cybersecurity stocks.

Even though we have been seeing very good performance for Big Tech stocks, it is rather not logical, as we are not seeing a widespread rally across all tech stocks.

I would like to bring our attention to $CNS Pharmaceuticals, Inc.(CNSP)$ which has appeared twice in the daily prediction and both days have quite significant gains.

17 Apr 23 - +17.02%, 20 Apr 23 - +48.02%

CNS Pharmaceuticals (CNSP)

CNS Pharmaceuticals is a clinical-stage pharmaceutical company which develop a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies.

They have a lead drug candidate, Berubicin. This drug candidate is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

https://cnspharma.com/

Future forward looking potential

This is from one of their news : “CNS Pharmaceuticals aims to undertake an interim analysis expected sometime in the third quarter of 2023. This pre-planned, non-binding futility analysis will include additional evaluation of safety and secondary efficacy endpoint. Thus, the latest enrollment continues the company’s progress toward the interim analysis… As a result of this expanded enrolment, CNS Pharmaceuticals has so far opened over 40 out of 59 clinical trial sites selected across Switzerland, Spain, France, Italy, and the U.S.”

Even though the stock price now is going below $2, I would see it as a good opportunity to load up before we go into Q3 2023.

I look forward to what CNSP will be sharing at the virtual investor spotlight event.

I will share more on A.I. Daily prediction along the way.

Sentiment Analysis For CNSP

The sentiment for CNSP has been picking up since late Mar 23, when there are news of approval from the competent authority and central ethics.

There are more news in the middle of April 2023 which fuel the stock price increase when they grow the region of its portfolios. This would make this stock attractive as its growth have been quite well timed.

Stock prices increase was normally delayed for pharmaceutical stocks as it will take time for investors and the market to comprehend the results of any trial or test.

Summary

Overall, I find that this is one of the better pharmaceutical stock which I would start researching and monitoring to place into defensive stocks.

We might be overwhelmed by the recent big earnings report from major tech stocks, but there are still risks of banking deposits issue, global economic condition plus the geopolitical condition which might shift the market.

Appreciate if you could share your thoughts in the comment section on what are your thoughts of looking to add pharmaceutical stocks as defensive stocks?

Do like, share and comment on this article if you find this trading thought useful.

@TigerStars appreciate if you could feature this article so that fellow tiger would benefit from my investing and trading thoughts.

Disclaimer: The analysis and result presented does not recommend or suggest any investing in the said stock. This is purely for Analysis.